Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05331053 · ClinicalTrials.gov registry record · Phase 4
MicroRNA Activation of LOX-1 Mechanisms in Endometriosis
A Phase 4 study, sponsored by Penn State University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT05331053 is a Phase 4 study that was terminated before completion, run by Penn State University. The registered enrollment target is 6 participants.
The verdict
NCT05331053, a Phase 4 study, was terminated before completion, sponsored by Penn State University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Endometriosis is a disorder that occurs in women. With endometriosis, tissue that should be found in the womb is found in sites outside of the womb. This disorder impairs the function of the cells that line the body's blood vessels (endothelium). The endothelium helps to control blood flow in healthy vessels. Women with this disorder have an increased risk for high blood pressure and high cholesterol. They have a higher risk for cardiovascular disease, too. With this study, we will learn how endometriosis impairs the lining of blood vessels and increases the risk for disease.
Interventions
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05331053
The ClinicalTrials.gov registry entry for NCT05331053 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Penn State University, which has 219 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atorvastatin is the first listed.
NCT05331053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05331053 about?
NCT05331053 is a clinical study titled "MicroRNA Activation of LOX-1 Mechanisms in Endometriosis". Endometriosis is a disorder that occurs in women. With endometriosis, tissue that should be found in the womb is found in sites outside of the womb. This disorder impairs the function of the cells that line the body's blood vessels (endothelium). The endothelium helps to control blood flow in health...
What is the current status of trial NCT05331053?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-05-01. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT05331053?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT05331053?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.